Genmab — Maj 2020

[Legolas23]

Det er set tidligere op til gode nyheder eller forventninger..

[kkjoel]

Tilfældingfandt den her fra JNJs 2020Q1-præsentation (14.04) af deres "Selected late stage development/registration" og "Selected NME (New Molecular Entity) pipeline". Amivantamab (JNJ-6372) og de 2 andre GEN bsMabs allerede fremhævet som potentielle blockbusters (JNJ-7564/7957) optræder alle under kolonneoverskriften "NME planned filings 20-23". Der har sikkert været linket til den før, men hva pokker...

[kkjoel]

Just a moment...

(www.investor.jnj.com)

[transalp]

Go morgen.. mit kaffegrums siger at vi holder os i det grønne idag.. der er for meget damp på maskinen, købere til de evt ekstra aktier der kommer i dag..

[Helge_LarsenPI-redaktør]

God morgen.

[bibob]

God morgen.

[Helge_LarsenPI-redaktør]

dara vs Sarclisa (GEN): https://www.proinvestor.com/debat/84218#84220

[bibob]

Nyt studie med Ofatumumab. ( ARTIOS ) . Ved ikke om det har været postet. https://www.clinicaltrials.gov/ct2/show/NCT04353492?term=Ofatumumab&draw=1&rank=4

[E_L]

From BioNTech SE (BNTX) Q1 2020 Earnings Call Transcript https://www.fool.com/earnings/call-transcripts/2020/05/13/biontech-se-bntx-q1-2020-earnings-call-transcript.aspx

[E_L]

"For our next-generation checkpoint-immune modulatory program partnered with Genmab, the ongoing trial with BNT311, the PD-L1x4-1BB dual body, continues to advance rapidly, as the expansion cohort has been initiated. Data from this Phase 1/2 trial in multiple solid tumors is expected in the second half of this year. We expect the updates to include dose escalation and safety data from the trial. We are excited about this program.

[E_L]

We believe it has broad potential in a range of solid tumors, including those where checkpoint therapy is currently established but also more difficult tumors where first-generation checkpoint inhibitors have not been as successful. This bispecific antibody has outperformed conventional checkpoint inhibitors in preclinical animal models. We have seen strong evidence in the preclinical setting of its ability to amplify the effect of our vaccines as well."

[E_L]

vaccines...?

[E_L]

BioNTech is trying PD1-/PD-L1
Inhibitors with their mRNA Cancer vaccines in Melanoma; i wonder if this could be an area where the PD-L1x4-1BB duobody could be used instead?

[Sukkeralf]

I Guess so E L based on your comments from the transcript - lots of opportunities going forward with this program if the initial phase I/II data are good

[Sukkeralf]

And both Genmab and BioNTech seems quite thrilled so far - actualy it could be even a bigger product than Darzalex but thats years ahead from now and lots of hills or even mountains to climb

[nohope]

Has anybody ever gotten an approval for a mRNA vaccine ?

[E_L]

no, not yet

[nohope]

Well, I guess this what they call a really long shot in english.

[E_L]

sure. on the other hand, there has never been as much focus and as much research into mRNA as now, due to Covid, surely could lead to something

[nohope]

Yes, really comforting right ? The destiny of the world depends on a technique that has never had a positive outcome.